UnitedHealth Group (UNH) Receives Buy Rating from Cleveland Research

Cleveland Research restated their buy rating on shares of UnitedHealth Group (NYSE:UNH) in a research note released on Friday.

Other equities analysts also recently issued reports about the stock. Raymond James boosted their price target on shares of UnitedHealth Group from $285.00 to $304.00 and gave the stock a strong-buy rating in a report on Monday, September 24th. Piper Jaffray Companies boosted their price objective on UnitedHealth Group to $312.00 and gave the company an overweight rating in a research note on Wednesday, November 28th. Cantor Fitzgerald restated a buy rating and issued a $310.00 price objective on shares of UnitedHealth Group in a research note on Wednesday, November 21st. Zacks Investment Research upgraded UnitedHealth Group from a hold rating to a buy rating and set a $299.00 price objective on the stock in a research note on Tuesday, September 25th. Finally, Oppenheimer boosted their price objective on UnitedHealth Group from $276.00 to $295.00 and gave the company an outperform rating in a research note on Wednesday, October 17th. One investment analyst has rated the stock with a hold rating and twenty-three have issued a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $292.33.

Shares of NYSE:UNH traded up $2.80 during midday trading on Friday, reaching $247.67. The company had a trading volume of 3,861,855 shares, compared to its average volume of 4,061,377. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.69 and a current ratio of 0.69. The company has a market capitalization of $234.39 billion, a P/E ratio of 24.59, a price-to-earnings-growth ratio of 1.23 and a beta of 0.88. UnitedHealth Group has a 52-week low of $208.48 and a 52-week high of $287.94.

UnitedHealth Group (NYSE:UNH) last issued its quarterly earnings results on Tuesday, October 16th. The healthcare conglomerate reported $3.41 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.30 by $0.11. The company had revenue of $56.56 billion for the quarter, compared to the consensus estimate of $56.34 billion. UnitedHealth Group had a net margin of 5.71% and a return on equity of 23.62%. The firm’s quarterly revenue was up 12.4% on a year-over-year basis. During the same period in the previous year, the firm earned $2.66 EPS. As a group, research analysts predict that UnitedHealth Group will post 12.81 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Thursday, December 13th. Stockholders of record on Monday, December 3rd were given a dividend of $0.90 per share. This represents a $3.60 annualized dividend and a dividend yield of 1.45%. The ex-dividend date was Friday, November 30th. UnitedHealth Group’s dividend payout ratio is presently 35.75%.

In other news, Director Kenneth Irwin Shine sold 163 shares of the company’s stock in a transaction dated Friday, November 9th. The stock was sold at an average price of $274.83, for a total transaction of $44,797.29. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Richard T. Burke sold 6,090 shares of the company’s stock in a transaction dated Wednesday, November 28th. The shares were sold at an average price of $281.72, for a total value of $1,715,674.80. Following the sale, the director now owns 1,711,584 shares in the company, valued at $482,187,444.48. The disclosure for this sale can be found here. Corporate insiders own 0.87% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. IMS Capital Management purchased a new stake in UnitedHealth Group in the third quarter worth approximately $85,000. Worth Venture Partners LLC purchased a new stake in UnitedHealth Group in the third quarter worth approximately $104,000. FNY Investment Advisers LLC purchased a new stake in UnitedHealth Group in the third quarter worth approximately $106,000. Fort L.P. purchased a new stake in UnitedHealth Group in the second quarter worth approximately $119,000. Finally, Polaris Greystone Financial Group LLC purchased a new stake in UnitedHealth Group in the third quarter worth approximately $120,000. Hedge funds and other institutional investors own 85.28% of the company’s stock.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.

Read More: What are the reasons investors use put options?

Analyst Recommendations for UnitedHealth Group (NYSE:UNH)

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit